The journal Nature recently publishes a new study of French researchers: they found through laboratory studies involving in recombinant horse proteins that T cell surface hidden in HIV specific express a protein called CD32a, while this protein has not been detected in the uninfected HIV T cells. This means that CD32a protein can be used as a biological target for the development of new drugs for "stealth" state HIV.

As HIV takes part of the immune, lymph and even intestinal cells as "stealth", the existing drugs and immune systems are unable to identify their "identity", leading to the condition that AIDS can’t be cured for many years. The reliance of these infected cells, which have been hidden deep, has been the most desirable candidate for HIV researchers, but it has had little success in 20 years.

This time, virologist Monceph bin Gillina at the University of Montpellier led the team in the laboratory to make T cells exposed to fluorescently labeled HIV, trying to find the difference in gene expression between T cells infected with HIV and not infected with HIV. As a result, they found that the infected T cells had a gene switch that encodes the CD32a protein and that the gene was not detected in the untagated T cells. They subsequently binds to the CD32a protein with an antibody that successfully extracts the cells that express the protein from HIV-infected blood samples and confirms that they are "latent" to T cells that are HIV and remain dormant. "It was a new breakthrough that could not have been done," said Benjirana, "Because it was impossible to identify these latent virus-carrying cells for years to find ways to attack them."

University of California virologist Stephen Dick is very excited about this new discovery, thinking that taking CD32a as a new target may can help to find the drugs to cure AIDS. But before the need for further research: First, to verify whether we can screen T cells expressing CD32a protein in patient blood samples with different gender, age and pathogenesis; Second, to detect the intestinal and lymph nodes and other HIV-infected tissues to detect whether there have the same expression of CD32a protein. By the way, Flarebio offers good-quality recombinant proteins including recombinant ITGB5 at good prices.